Moreover, the combination of chemokine receptor (including CCR2b and CXCR5) and IL-7 armoring has been demonstrated to boost CAR T-cell expansion and anti-tumor activity in immunodeficient mouse tumor models (187, 188). This evidence concerns the gene CXCR5 and neoplasm.